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Abstract
Phosphoinositide kinases regulate diverse cellular functions and are important targets for therapeutic development for
diseases, such as diabetes and cancer. Preparation of the lipid substrate is crucial for the development of a robust and
miniaturizable lipid kinase assay. Enzymatic assays for phosphoinositide kinases often use lipid substrates prepared from
lyophilized lipid preparations by sonication, which result in variability in the liposome size from preparation to preparation.
Herein, we report a homogeneous 1536-well luciferase-coupled bioluminescence assay for PI5P4Ka. The substrate
preparation is novel and allows the rapid production of a DMSO-containing substrate solution without the need for lengthy
liposome preparation protocols, thus enabling the scale-up of this traditionally difficult type of assay. The Z’-factor value
was greater than 0.7 for the PI5P4Ka assay, indicating its suitability for high-throughput screening applications. Tyrphostin
AG-82 had been identified as an inhibitor of PI5P4Ka by assessing the degree of phospho transfer of c-
32P-ATP to PI5P; its
inhibitory activity against PI5P4Ka was confirmed in the present miniaturized assay. From a pilot screen of a library of
bioactive compounds, another tyrphostin, I-OMe tyrphostin AG-538 (I-OMe-AG-538), was identified as an ATP-competitive
inhibitor of PI5P4Ka with an IC50 of 1 mM, affirming the suitability of the assay for inhibitor discovery campaigns. This
homogeneous assay may apply to other lipid kinases and should help in the identification of leads for this class of enzymes
by enabling high-throughput screening efforts.
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Introduction
Phosphatidylinositol (PI) signaling has been shown to impact
a variety of fundamental cellular processes, including intracellular
membrane trafficking, cytoskeletal rearrangement, cell prolifera-
tion, survival and growth. Dysregulation of these pathways can
lead to cancer and other diseases [1,2,3,4,5,6]. Phosphoinositides
contain two fatty-acid chains linked through a diacylglycerol
moiety and phosphodiester bond to an inositol headgroup. PIs are
an important class of lipids that are regulated by reversible
phosphorylation of the inositol headgroup. Phosphatidylinositides
have three main phosphorylation sites on the inositol (positions 3,
4 and 5) that are regulated by different classes of phosphoinositide
kinases and phosphatases. The three phosphatidylinositol mono-
phosphates (PIPs) are PI3P, PI4P and PI5P. Importantly, these
regioisomers have distinct roles in vivo, and there are three types of
kinases (PIPKs) that distinguish and phosphorylate specific PIPs
[7,8,9]. Type I PIP kinases (PI4P 5-kinases/PI4P5Ks) preferen-
tially phosphorylate PI4P on the 5 position, Type III PIP kinases
(PI5P 3-kinases/PI3P5Ks/Fab1/PIKfyve) preferentially phos-
phorylate PI3P on the 5 position, and Type II kinases (PI5P 4-
kinases/PI5P4K), which are the focus of the present report,
preferentially phosphorylate PI5P on the 4 position as shown in
Figure 1 [10].
There has been a massive expansion in the investigation of the
function and role of PI3K after the discovery of the phosphoinosi-
tide-3-kinase (PI3K) inhibitors wortmannin and LY294002
[11,12]. While PI5P4K is known to play a role in insulin signaling,
megakaryocyte development, and Vitamin-D signaling
[13,14,15,16], to date there are no commercially-available
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Recently, Demian et al. have demonstrated that selective inhibitors
against PI5P4K can be obtained from screening [17]. However,
potent PI5P4K inhibitors are still not available and such
compounds would serve as valuable research tools to investigate
the physiological role of PI5P4K activity.
The PIPKs share very little sequence homology with protein or
other lipid kinases, which may facilitate the design of selective
inhibitors. PI5P4Kb has been crystallographically characterized
and shows a flattened lysine-containing basic patch that is
expected to bind to the phospholipid headgroup on the surface
of the lipid membrane [18,19]. PI5P4Ka and PI5P4Kc also have
crystal structures available (PDB ID:2YBX and 2GK9), and they
show a similar overall structure. A binding assay and an enzymatic
assay that utilized an elaborate liposome-based substrate prepa-
ration have been previously reported [17,18]. Additionally, low-
throughput radiolabeled enzymatic thin layer chromatography
(TLC) assays were developed where the substrate was prepared in
an isotonic KCl solution or as a liposome mixture [20,21]. The
radiometric assay uses c-
32P-ATP and PI5P and measures
radiolabeled enzymatic product, PI(4,5)P2 after the separation by
TLC [10,22,23]. There is, however, a need for additional assay
types with simplified reproducible substrate preparations that are
amenable to high-throughput screening.
We sought to establish a 1536-well compatible high-throughput
enzymatic assay for PI5P4Ka to enable large multi-day library
screens. A novel substrate preparation was developed that yielded
a stable solution amenable to large-scale screening and that could
be prepared reproducibly in house with common laboratory tools.
Furthermore, the new assay was employed in a small library
screen, resulting in the identification of an ATP-competitive
tyrphostin (TYRosine PHOSphorylation INhibitors) inhibitor of
PI5P4Ka (IC50=1mM). This new high-throughput screening
methodology should enable large library screening to help identify
selective inhibitors of PI5P4Ka and related enzymes.
Materials and Methods
Reagents and Consumables
Hepes, pH 7.4 (4-(2-Hydroxyethyl)-1-piperazine ethanesulfonic
acid) and MgCl2 were purchased from GIBCO (Carlsbad, CA,
USA) and Quality Biological Inc. (Gaithersburg, MD, USA),
respectively. EGTA, tyrphostin I-OMe-AG-538 and CHAPS (3-
[(3-Cholamidopropyl)dimethylammonio]propanesulfonic acid)
were purchased from Sigma-Aldrich (St. Louis, MO, USA).
Dimethyl sulfoxide (DMSO, certified ACS grade) was obtained
from Thermo-Fisher Scientific (Pittsburg, PA, USA). Tyrphostin
25 (AG-82) was purchased from Cayman Chemical Company
(Ann Arbor, MI, USA). Medium binding white solid-bottom 1536-
well plates (assay plates), 1536-well polypropylene plates (com-
pound plates) and 384-well white solid-bottom plates were
purchased from Greiner Bio One (Monroe, NC, USA). The
384-well polypropylene V-bottom plates (compound storage) were
from Matrix/Thermo Scientific (Hudson, NH, USA). Biolumi-
nescent assay detection used the Promega ADP-Glo kit (Madison,
WI, USA), which came with 10 mM Ultrapure ATP that was used
for the assay. Per the manufacturer’s protocol, this kit can be used
for reactions containing between 1 mM to 1 mM ATP. PI5P4Ka
with a GST tag was expressed and purified as described previously
[10]. A 0.4 mg/mL stock was stored at 280uC and used for this
work.
Compound Library
The library of pharmacologically active compounds (LO-
PAC
1280, Sigma-Aldrich) contains 1280 known bioactives that
were received as 10 mM DMSO solutions. The compound library
was plated in 1536-well format with an Evolution P
3 (EP
3) liquid
dispenser (Perkin Elmer, Shelton, CT, USA). The library was
formatted into columns 5–48 of 1536-well compound plates at 4
stock concentrations (1: 5 dilution, spanning the 10000 to 80 mM
range) and 5 mL per well. Preparation of the compound library for
quantitative high-throughput screening (qHTS) has been de-
scribed previously [24]. A control plate was made in a compound
plate in columns 1–4 using a Cybi-Well (CyBio, Jena, Germany) to
transfer solutions from a 384 compound storage plate to the 1536
plate compound plate. Columns 1, 3, and 4 contained DMSO and
column 2 contained a 1:2 serial dilution of the control compound
tyrphostin AG-82 (16 points with N=2 and starting concentration
of 100 mM).
Lipid Preparation
DPPS (1,2-dipalmitoyl-sn-glycero-3-phosphoserine) and PI5P
(D-myo-phosphatidylinositol 5-phosphate diC16) were purchased
from Echelon Biosciences (Salt Lake City, UT, USA). DPPS was
dissolved in DMSO and sonicated for one minute (using
a sonicating water bath) and mixed by vortexing for 30 seconds,
thereby forming a clear solution (333 mL DMSO per 1 mg DPPS).
PI5P was suspended in DMSO and mixed by sonication and
vortexing for several minutes (333 mL DMSO per 1 mg PI5P). A
2:1 ratio of DPPS to PI5P was then made (500 mL of PI5P,
1000 mL of DPPS plus an additional 1500 mL of DMSO), and the
resulting lipid mixture was sonicated and mixed by vortexing for
Figure 1. Schematic representation of the PI5P4K reaction
using PI5P as the substrate. The additional carrier substrate DPPS is
not shown.
doi:10.1371/journal.pone.0054127.g001
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was found to be stable for at least six cycles of freeze/thaw.
On the day of the experiment, the lipid mix was thawed and
mixed by sonication and vortexing for one minute. For each step
up until the enzyme addition, each reagent addition was followed
by a brief sonication and vortex mixing step. First, 1259 mL of the
lipid mix was added to 315 mL of DMSO. Then, 5827 mLo f
buffer 1 (30 mM Hepes pH 7.4, 1 mM EGTA, 0.1% CHAPS)
was added and lastly, 13525 mL of buffer 2 (46 mM Hepes
pH 7.4, 0.1% CHAPS) was added. This lipid reagent was used for
the assay as described below. All lipid mixtures were prepared in
glass vessels to minimize surface absorption.
Miniaturized Enzyme Activity Assay
PI5P4Ka (52.4 mL) was added to the lipid reagent (3 mL,
described above) to form the enzyme-lipid mixture. First, 2 mLo f
the enzyme/lipid substrate reagent (2 mg/mL PI5P4Ka final
concentration) were dispensed into a white solid-bottom 1536-well
plate in columns 1–2, 4–48 using a Flying Reagent Dispenser
(FRD, Beckman Coulter, Fullerton, CA, USA). Into columns 3
and 4, 2 mL of a no-lipid and no-enzyme control were dispensed,
respectively, where the lipid was replaced by DMSO or the
enzyme was replaced by buffer (20 mM Hepes 7.4, 0.1% CHAPS)
in the enzyme-lipid mixture. Then, 23 nL of the library
compounds and control compounds were transferred by a 1536
pintool (Kalypsys Systems, San Diego, CA, USA) into wells 5–48
and 1–4, respectively. To initiate the reaction, 1 mL of the ATP
solution (20 mM Hepes pH 7.4, 60 mM MgCl2, 0.015 mM ATP
and 0.1% CHAPS) was added. The final concentration of DMSO
in the reaction was 5%. The resulting mixture was incubated at
room temperature in the dark for one hour, at which time 2 mLo f
ADP-Glo reagent 1 were added to stop the reaction and remove
any remaining ATP. After a 45-minute incubation, 4 mL of the
ADP-Glo reagent 2 were added and allowed to incubate for 30
minutes. The luminescence was then read with a ViewLux high-
throughput CCD imager (Perkin Elmer, Waltham, MA, USA). A
total of six plates were assayed: one DMSO plate for monitoring
the background trends and five concentrations of the LOPAC
library (152, 76, 15, 3 and 0.6 mM final assay concentrations,
respectively). The top concentration in the assay was attained by
two sequential pin transfers of the top concentration of the
compound library.
Data Analysis
Screening data were corrected and normalized, and concen-
tration-response curves were derived using in-house algorithms
[25]. Overall assay performance, including trends in Z’ factor, %
CV, and S/B, were recorded. Percent activity was computed after
normalization using the median values of the uninhibited enzyme
control (32 wells in column 1) and the no-enzyme, or 100%
inhibited, control (32 wells, column 4). Additionally, the
compound structures were evaluated, and the long chain
compounds such as the C18 containing compounds from
LOPAC
1280 that are likely to act by disrupting the lipid vesicles
were eliminated. Selected actives were procured for re-testing in
the primary screening assay and for use in the counter assays and
substrate competition assay.
c-
32P-ATP Incorporation Assay and TLC
The PI5P4K assay was carried out as described in [10,22,23].
Briefly, the kinase reaction was carried out in a total of 50 mLo f
kinase buffer containing 20 mL of the resuspended lipids, 50 mM
HEPES pH 7.4, 10 mM MgCl2,1 0mM non-radiolabeled ATP,
10 mCi [c-
32P]-ATP with 0.1 mg of GST-PI5P4Ka for 7 minutes
at room temperature. The reaction was terminated by adding
20 mL of 4 N HCl. Phosphoinositides were extracted by adding
70 mL of methanol/chloroform (1:1, vol:vol) mix and subjected to
TLC (thin-layer chromatography) separation using heat-activated
2% oxaloacetate-coated silica gel 60 plates (20 cm620 cm, EMD
Chemicals Inc., Billerica, MA, USA) and a 1-propanol/2 M acetic
acid (65:35, vol:vol) solvent system. The radiolabeled product,
PI(4,5)P2, was quantified with a Phosphorimager (Molecular
Dynamics, STORM840, GE Healthcare, Waukesha, WI, USA).
Counterscreen Assays
After hit confirmation of the selected and reacquired com-
pounds in an 11-point retest in the qHTS ADP-Glo PI5P4Ka
assay, the compounds were tested for their effect on the detection
reagent. A firefly luciferase counterassay is available and has been
used previously but the ADP-Glo kit has an additional enzyme
that could be subject to compound interference, therefore a new
counterassay was utilized [26]. The same assay design as above
was used here except the lipid was replaced by DMSO and the
enzyme was replaced by 20 mM Hepes pH 7.4, 0.1% CHAPS
buffer. After 2 mL of the replica enzyme-lipid mix was added,
compounds were transferred by pintool into this buffer. Then, an
ADP/ATP mix representing 20% conversion levels (0.003 mM
ADP and 0.012 mM ATP) was added. The two-step ADP-Glo
detection kit was then used, and the luminescence was recorded as
described above.
Substrate Competition Assay
Seven concentrations of ATP (concentration in final reaction
was 0.25 Km, 0.5 Km,1K m, 1.5 Km,3K m,5K m and 10 Km,
where Km =5mM, the Km of ATP) were used to assess the effect
of ATP on the apparent IC50 of Tyrphostin I-OMe-AG-538. The
experiment was otherwise conducted as described above for the
miniaturized ADP-Glo enzyme assay.
Results and Discussion
Substrate Preparation
Preparation of the substrate is crucial for the development of
a robust and miniaturizable lipid kinase assay. Phosphatidylserine
(DPPS =1,2-dipalmitoyl-sn-glycero-3-phosphoserine) is often used
as a carrier for lipid substrates and was used in combination with
PI5P here (PI5P=D-myo-phosphatidylinositol 5-phosphate
diC16) [17,22,27]. We aimed to make a DPPS/PI5P lipid mix
in which the reagents would be stable for at least 8 hours and
would not be subject to settling or clumping during the repeat
dispensing steps. The main challenge originated from the di-
verging solubility and substrate competency trends by the lipids
under consideration: PI5P and DPPS can have different alkyl
chain lengths and the shorter ones (C4 and C8) are soluble in
buffer but are not substrates for PI5P4Ka (data not shown and
[17]), while the longer C16 PI5P4Ka substrates are not soluble in
buffer but are soluble in DMSO.
Previously, a binding assay was developed with sucrose-loaded
unilamellar vesicles that were then prepped by multiple freeze-
thaw cycles followed by extrusion [18]. The study investigated
a variety of lipid substrates and showed the importance of the
negative charge for binding of the lipid to PI5P4Ka. Demian et al.
previously established a 384-well enzymatic assay for PI5P4Ka
and PI5P4Kb using a translucent liposome-based presentation of
the substrate (2:1 ratio of phosphatidylserine to PI5P) [17]. They
had used a liposome suspension in buffer for their C16 lipid
substrate that was prepared by a time-consuming and technically
challenging method that involved mixing the two lipids in acidified
High-Throughput Lipid Kinase Assay
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buffer for 2-16 hours followed by repeated extrusion [17]. The
authors utilized a commercial vendor to make the liposomes
because the in-house preparations yielded variable results. That
assay was used to screen a kinase-focused compound library, and
a hit was identified and its binding to PI5P4Kb was confirmed
with additional biophysical characterization (IC50=0.5821.4 mM
depending on assay modality). During our attempts to adopt this
protocol (without the use of an extruder to which we had no
access) the substrate suspension was subject to rapid settling, and
even after sonication and vortexing there were large visible
particulates that were not amenable to 1536-well dispensing.
Breaking liposomes down into smaller sizes has been shown to
eliminate settling and perhaps an extruder step may have led to
a particle size amenable to overnight stability and dispensing of
small volumes without clogging the 1536-well dispenser [28]. The
substrate characteristics of insolubility, settling, and the apparent
necessity of commercial processing were not readily amenable to
affordable and flexible substrate preparation and further assay
miniaturization. Furthermore, large-scale robotic screening re-
quires the creation of large and stable batches of reagents to enable
continuous unattended robotic screening.
The method developed here allows the lipid substrate to be
prepared at the bench without the need for expensive specialized
equipment or processing. It was discovered that when the long-
chain DPPS and PI5P lipid components were brought up in
DMSO and mixed with just sonication and vortexing, a lipid-
containing homogeneous solution was formed. This solution was
not prone to settling and could be made reproducibly without the
need for costly commercial processing. This PI5P/DPPS solution
could then be added step-wise to buffer to yield a lipid solution
that was not prone to settling and did not have any visible
particulates. A flow chart describing the lipid substrate preparation
is shown in Figure 2. The detergent CHAPS (0.1%) was used in
the buffer to minimize enzyme, lipid, or compound sticking to
plastic as well as to limit aggregation of the compounds to be tested
[29]. The lipid substrate was found to be soluble in buffer with 5%
DMSO. Further stability and scalability testing of this substrate
preparation were performed during the assay and screen
implementation as described in the following sections.
Design and Miniaturization of the High-throughput
PI5P4Ka Enzyme Assay
To enable large-scale library screening, a 1536-well luciferase-
coupled bioluminescence PI5P4Ka assay was pursued. Our goal
was to design an enzymatic reaction whereby the enzyme, lipid
substrate, and ATP could be dispensed in two, rather than three,
distinct steps to minimize the overall variability of dispense, which
in turn required the combination of two of the reagents into one
vessel. Many kinases, including PI5P4Ka have low levels of
substrate-independent consumption of ATP, which precluded the
enzyme and ATP from being stored together. There was also
a spontaneous phospho transfer from ATP (by a very small
amount) to the lipid when these two reagents are stored together
(data not shown). The stability of the enzyme/lipid solution was
tested, and it was found that there was a less than 5% change in
activity for a premixed solution maintained at 4uC for 16 hours
versus a freshly prepared stock (see Figure 3A). Stability over 8
hours is ideal for the large robotic screens to allow for facile
reagent exchanges to be scheduled in a continuous robotic run.
This reagent configuration (enzyme/lipid followed by ATP) was
used in the assay.
The Km of ATP (5–6 mM) had been determined previously
[17,30], and the ATP concentration was set at the Km to ensure
that the assay would be sensitive to ATP-competitive inhibitors.
The substrate concentration was determined such that a reasonable
% ATP conversion (,20%) and robust assay statistics could be
obtained with a one-hour incubation time by 10 nM of PI5P4Ka
(see Figure 3B and Figure 4). A PI5P concentration of 75 mM was
determined to be optimal because 50 mM resulted in lower
enzyme activity and 100 mM gave nearly the same results as
75 mM. The Km of this substrate is unknown and could not be
measured here because the use of lipid concentrations much
higher than 100 mM, required for the accurate derivation of Km,
would lead to a DMSO concentration that is not well tolerated by
the enzyme (see following section). By having excess lipid relative
to the S0.5 (,50 mM), a slight loss of lipid sticking to the storage
bottle, dispenser tubing or assay plate during the HTS can be
tolerated without an appreciable change in assay performance.
The two-step ADP-Glo kit was used to detect the ADP product,
which allows for the development of a sensitive assay without the
need for high levels of conversion [31]. The detailed assay protocol
can be found in the Materials and Methods and is summarized in
Figure 2. Schematic representation of the 2:1 DPPS:PI5P lipid preparation protocol.
doi:10.1371/journal.pone.0054127.g002
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comparable when the substrate was prepared by the method of
Demian et al. and the method described here (S/B =12 -13,
Figure S1) [17], indicating that the new lipid preparation could
function as a substrate for PI5P4Ka. Additionally, the lipid
mixture was found to be stable to at least six rounds of freeze/thaw
(data not shown), which allows the substrate to be prepared and
validated in large batches and used for multiple experiments.
DMSO Tolerance
The effect of DMSO on the enzyme reaction was tested, and it
was found that up to 7.25% DMSO there was little effect on the
enzyme activity and assay performance. At high DMSO levels, the
concentration of DMSO used to make the enzyme-lipid reagent
was found to impact the ratio of lipid-coupled kinase ATPase
activity to lipid-independent kinase ATPase activity: 5% DMSO
was found to have very little lipid-independent kinase ATPase
activity (,4%) while allowing the lipid substrate to be readily
accessible to the enzyme active site; however, at DMSO
concentrations of greater than 15%, the amount of lipid-
independent phosphorylation increased dramatically (See Figure
S2). Therefore, DMSO at 5% was able to help solubilize the
substrate while retaining the desired substrate-coupled enzyme
activity, and this concentration of DMSO was used for the
miniaturized luciferase-coupled assay.
Pilot Screen
Validation of the PI5P4Ka assay was performed by a qHTS
(quantitative HTS, [25]) against the library of pharmacologically
active compounds (LOPAC
1280, Sigma-Aldrich) arrayed as a five-
point titration series (152, 76, 15, 3, and 0.61 mM final compound
concentration). Additionally, a vehicle only DMSO plate was run
and used to monitor the background. The validation experiment
showed excellent performance as measured by a stable signal:back-
ground ratio (12.6), stable Z’ factor (0.77) and a low CV (9.3%)
(Figure 4A–C). Tyrphostin AG-82 had been identified by
a radiometric assay that uses c-
32P-ATP and PI5P and measures
the radiolabeled enzymatic product, PI(4,5)P2, after separation by
Figure 3. Lipid dependence, overnight stability and control compound. (A) The overnight (16 hour) stability of the assay reagents at 4uC
when the enzyme and lipid were premixed, stored separately or made up fresh as compared to a no enzyme and 5 mM ADP (representing 0% and
100% conversion, respectively). The error bars represent the standard deviation (N=2). (B) The PI5P lipid dependence of the PI5P4Ka enzyme
reaction. The error bars represent the standard deviation (N=2) and are not discernable on the plot. (C) and (D) Tyrphostin AG-82 (AG82) was
identified as a weak inhibitor of PI5P4Ka (decreases the enzyme activity by 75%) by a radiometric assay that uses c-
32P-ATP and PI5P and measures
the radiolabeled enzymatic product, PI(4,5)P2 after the separation by thin layer chromatography. Five additional compounds were tested and found
not to significantly inhibit PI5P4Ka (AG17= tyrphostin AG-17, AG18= tyrphostin AG-18, MP=mycophenolate, PVB=purvalanol B and SU6668). All
compounds were tested at 100 mM, except for PVB, which was tested at 10 mM due to solubility limitations at higher concentrations. The raw image
and the extracted data are shown in (C) and (D), respectively. The commercial PI5P substrate predominantly contains two palmitate groups with
a very small amount of deacylated lipid lyso-PI5P that contains only one palmitate group. The intense top spots in (C) represent the PI(4,5)P2 product
with two palmitate groups, and the faint spots below represent the product with just one palmitate group.
doi:10.1371/journal.pone.0054127.g003
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activity at 100 mM in the radiometric assay (See Figure 3C) and
was used as a control compound here. It exhibited an excellent
MSR (Minimum Significant Ratio, [32]) of 1.29 (Figure 4D) in the
LOPAC
1280 screen and yielded an IC50 of 93 mM, which is
consistent with the observed 75% inhibition at 100 mM in the
radioassay. Importantly, the enzyme-substrate solution was not
prone to settling and did not require mixing during dispense of
multiple plates, as evidenced by the successful scale-up experiment
performed on a fully-automated robotic platform (See Figure S3).
Figure 4. Performance of the PI5P4Ka assay in 1536-well assay plates. (A) Z’ factor, (B) signal/background, and (C) % column variance as
a function of assay plate. An average Z’ =0.7760.04, S/B =12.661.04 and % CV =9.3262.1 was achieved for the six plates (reported as average 6
standard deviation). (D) IC50 data for the control compound AG-82 on the six assay plates depicted with six symbols. MSR of the IC50=1.29. Each plate
contained 2 16-pt titrations, which were averaged, and the standard deviation is depicted as error bars on the plot (N=2).
doi:10.1371/journal.pone.0054127.g004
Table 1. Steps of the High-Throughput PI5P4Ka Assay.
Step Parameter Value Description
1 Enzyme/Lipid 2 mL Enzyme/lipid, no enzyme and no lipid solutions; reagent bottles are kept on ice
2 Centrifugation 10 sec Spin 3006g
3 Library and Control Compounds 23 nL 152, 76, 15, 3 and 0.61 mM final concentration titration series of library and 769 mM AG-82 1:2 16-
point control titration.
4 Substrate 1 mL ATP, room temperature
5 Incubation time 60 min Room temperature
6 ADP-Glo Reagent 1 2 mL ADP-Glo detection reagent 1 at room temperature
7 Incubation time 40 min Room temperature
8 ADP-Glo Reagent 2 4 mL ADP-Glo detection reagent 2 at room temperature; reagent bottle is protected from light
9 Incubation time 30 min Room temperature
10 Assay Readout Luminescence ViewLux in end-point mode: 20 second exposure
Step Notes.
1. Dispensed into white solid-bottom 1536-well MB Greiner plates with a Flying Reagent Dispenser (FRD). Reagent is kept on ice. Final concentration is 10 nM PI5P4Ka,
75 mM PI5P and 150 mM DPPS.
2. Plates centrifuged at 3006g for 10 seconds.
3. DMSO compound solutions transferred with a Kalypsys pintool.
4. Dispensed with a FRD. Final concentration is 5 mM ATP.
5. Plates incubated at room temperature.
6. Dispensed with a FRD.
7. Plates incubated at room temperature.
8. Dispensed with a FRD.
9. Plates incubated at room temperature.
10. Luminescence was measured with a ViewLux CCD Imager with a 20 second exposure time.
doi:10.1371/journal.pone.0054127.t001
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equation was performed using in-house methods and is detailed
in the Materials and Methods section. Of the 1,280 LOPAC
compounds screened, a total of 32 compounds were identified with
upper and lower asymptotes in their concentration responses and
an efficacy of over 80%.
The LOPAC
1280 library contains many tyrphostins and indeed
several analogues of the AG-82 (Tyrphostin 25) control with
a range of potencies (IC50s of 2.5 mM to over 100 mM, Figure 5A)
were identified. The most potent analogue, I-OMe-tyrphostin AG-
538 (I-OMe-AG-538), had an IC50 of 2.5 mM. Additionally, long-
chain compounds, such as 1-O-Octadecyl-2-O-methyl-sn-glycero-
3-phosphorylcholine, were identified as inhibitors. These com-
pounds may be acting through prevention of lipid substrate
binding to PI5P4K.
Seven of the initial hits were reacquired and tested as 11-point
titrations in the PI5P4Ka enzyme assay. The activity of all of these
inhibitors was reconfirmed indicating the reproducibility of the
assay. The IC50 was determined to be 1 mM for a freshly plated
stock of I-OMe-AG-538.
Counterscreen Assay on Selected Hits
When developing a screen, it is important to assess the type of
compounds that could interfere with the detection. For the assay
developed here, the formation of the product ADP is detected by
a coupled assay system that contains several enzymes [31,33,34].
Compounds that impact these detection components could be
erroneously identified as actives, so a facile assay was developed to
test for compounds that interfere with this detection system.
Previously, compounds have been identified that interact with the
firefly luciferase system, one of the components in the ADP-Glo kit
[35]. It is possible and indeed recommended to screen apparent
hits in a luciferase-coupled assay against the luciferase enzyme
itself [36]. Furthermore, ADP-Glo contains additional enzymes
that may also be subject to compound interference, making
a counterscreen for any apparent hits using the full ADP-Glo kit
very important. The selected compounds from the screen were
tested in an assay where a fixed concentration of ADP/ATP,
representing 20% conversion, is present in the absence of the
enzyme and lipid, and the detection system was used to quantitate
the ADP. If the compound does not act on the detection system,
the amount of luminescence, which correlates with the amount of
ADP, should not differ between wells with compound and wells
with DMSO. If, however, the compound interferes with the
detection system, apparent IC50 values would be obtained for the
compound titration. The compounds were found to be free of
effects against the detection in the ADP-Glo detection system
(Figure 5B), indicating that the compound IC50 values that were
obtained in the PI5P4Ka assay were due to the effect of the
compound on the enzyme reaction itself and not on the detection
reagents.
ATP Competition
To help identify the mode of inhibition of I-OMe-AG-538, the
IC50 was measured using the miniaturized ADP-Glo assay in the
presence of seven concentrations of ATP spanning 0.25xKm to
106Km of ATP. By the slope of the resulting data plotted as IC50
vs. [ATP]/Km, the inhibitor can be determined to be a non-, un-
or competitive inhibitor with ATP [37]. Figure 6 shows a positive
relationship between the [ATP]/Km and the IC50 indicating
competitive inhibition, i.e. that the inhibitor and ATP cannot bind
to the enzyme in an orthosteric mode. Additionally, the Ki was
determined to be 0.5 mM. Tyrphostin AG-538 (AG-538) inhibits
insulin-like growth factor 1 receptor (IGF1R) with an IC50 of
60 nM and is competitive with respect to substrate for IGF1R
[38]. Both AG-538 and I-OMe-AG-538 inhibited IGF1R in
a similar dose-dependent manner in a cell assay [38]. Modeling
showed that the tyrosines in the substrate overlaid with the
catechols in AG-538 and that AG-538 mimics the substrate [38].
For PI5P4Ka, however, I-OMe-AG-538 does not resemble the
substrate PI5P. Indeed, tyrphostins have been shown previously to
be ATP competitive, substrate competitive and competitive with
both substrate and ATP [39,40]. Although we did identify a few
compounds such as oleamide and OMDM-2 ((R)-N-oleoyl
Tyrosinol), which were found to be weak inhibitors (IC50s
,30 mM), whose potency did not vary with ATP, and could
therefore interact with the lipid pocket, we were not able to vary
lipid in the present assay configuration, due to the limited
solubility of the lipid substrate. As well, if the lipid concentration
was increased to look for competition, the DMSO concentration
would increase, and the enzyme would uncouple from its
substrate, making it impossible to conduct this experiment. To
assess lipid competition, either a higher concentration of substrate
in DMSO would need to be tried or the commercial liposome
Figure 5. Confirmation of inhibitors. (A) i, The IC50 inhibition curves of the tyrphostin analogues identified from the Lopac library are shown.
Numbers refer to the tyrphostin analog and IC50s were determined to be as follows: tyrphostin I-OMe-AG-538 (2 mM), tyrphostin 51 (5 mM), tyrphostin
AG 112 (13 mM), tyrphostin AG 538 (14 mM), tyrphostin AG 808 (18 mM), tyrphostin 47 (20 mM), tyrphostin AG 537 (32 mM), tyrphostin 23 (45 mM),
tyrphostin AG 555 (50 mM), tyrphostin AG 698 (50 mM), tyrphostin AG 490 (89 mM), tyrphostin AG 494 (89 mM), tyrphostin AG 1478 (100 mM). ii,
Structures of the four most potent tyrphostin analogs. (B) The IC50 curves with standard deviation error bars (N=2) of tyrphostin I-OMe-AG-538 in the
PI5P4Ka assay (squares) and the counterscreen (open circles).
doi:10.1371/journal.pone.0054127.g005
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as surface plasmon resonance using lipid-coupled sensor chips,
could be employed to determine the mechanism of action in
regards to substrate competition.
Conclusions
In conclusion, this new and validated luciferase-coupled bio-
luminescence 1536-well PI5P4Ka assay entails a lipid preparation
that is more facile and less costly than earlier assay designs for the
important drug targets PI5P4Ka/PI5P4Kb. The lipid could be
solubilized in DMSO with just sonication and vortex mixing on
the benchtop. The enzyme/lipid mixture is stable overnight and
did not require additional stirring during the course of our screens.
The IC50 of the control compound measured in this assay was
corroborated by the orthogonal thin layer chromatography
radiolabeled ATP assay. Inhibitors were identified in the
miniaturized ADP-Glo assay that reconfirmed upon reacquisition,
and they were found to be free of interference with the detection
system. The tyrphostin molecule I-OMe-AG-538 was shown to be
competitive with respect to ATP for binding to PI5P4Ka and to
have an IC50 of 1 mM. This new facile substrate preparation and
assay method can be expanded to other lipid kinase family
members for which the more labor-intensive liposome methods
have been used and should enable the large-scale screening of
libraries, such as the Molecular Libraries Small Molecule Re-
pository (MLSMR) library that contains nearly 400,000 com-
pounds.
Supporting Information
Figure S1 Assay performance comparison. Comparison of
assay performance of the luciferase-coupled assay system using the
lipid prepared in DMSO and the lipid prepared from lipid cakes.
The luminescence from enzyme and no enzyme preparations
using the lyophilized lipid cakes sonicated in buffer method (black)
and the DMSO method (checkered) are shown. Standard
deviation error bars are shown (N=2).
(TIF)
Figure S2 DMSO effect on the performance of the
luciferase-coupled assay system. DMSO concentrations
were tested from 5–30%. Testing below 5% DMSO was not
feasible due to the requirement of DMSO for solubilization of the
substrate. Standard deviation error bars are shown (N=2).
(TIF)
Figure S3 Assay performance on robotic system. Stable
performance of the PI5P4Ka assay was obtained in the 1536-well
assay scale-up experiment performed on a fully-automated robotic
platform [41] (147 plates tested). The Z’ factor is shown as
a function of assay plate.
(TIF)
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